Healthcare IT Today

AI Insights in Pharma with Protai - Life Sciences Today Podcast Episode 50

In episode 50 of the Life Sciences Today podcast, host Danny Lieberman sits down with Carol Pesner, CTO and co‑founder of ProtAI, to discuss the company’s AI‑driven approach to drug discovery. ProtAI fuses structural proteomics with advanced artificial intelligence to generate sub‑atomic resolution models of target proteins, a capability they argue surpasses the average‑case performance of AlphaFold, the Nobel‑winning protein‑folding AI. The conversation highlights how this high‑resolution modeling enables rapid design of small‑molecule therapeutics, exemplified by their lead candidate for estrogen‑receptor positive breast cancer, which they expect to enter clinical trials within a year. By integrating proprietary proteomics data with AI, ProtAI claims to accelerate candidate selection from the industry‑standard three‑year timeline down to roughly twelve months, dramatically cutting cost and risk. Listeners hear concrete examples, such as the company’s internal pipeline progress and its collaborative licensing strategy with pharma and biotech partners. Pesner emphasizes that while AI informs decision‑making, experimental validation remains the ultimate proof, and the firm safeguards its advantage through unique in‑house datasets and chemical‑matter IP. The broader implication is a potential shift in the drug‑development ecosystem: technology firms that not only provide platforms but also bring drugs to market can capture greater value, challenge traditional R&D timelines, and offer pharma partners faster, more precise therapeutic candidates.